Published in AIDS Weekly, September 29th, 1997
GEM 92 is a second generation, mixed backbone antisense compound for the treatment of HIV and AIDS. GEM 92 targets the gag site in the HIV genome. Hybridon believes that this is the first study in humans to investigate the potential for oral delivery of an antisense oligonucleotide.
The company has planned to conduct the clinical trial in the United Kingdom and expects the trial to involve approximately 13 normal volunteers. The company intends to administer to each volunteer a single dose at one of three dose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.